Tests stopping HIV treatment in selected adults living with HIV
Tests a planned pause of HIV treatment in selected adults with HIV.
Plain-language title generated from the registry record
Registry title: A Clinical Trial of Analytical Treatment Interruption in People With HIV With a Highly Favourable Profile
Key facts
- Where
- Barcelona, SpainSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07875504, who can take part
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacion Clinic per a la Recerca Biomédica
- Trial code
- NCT07875504EU 2026-526395-23-00
- Record updated
- 15 October 2026
- Original description
A pilot single exploratory clinical trial of ATI in a selected sample of PWH sharing specific genetic, phenotypic and clinical characteristics.Read full original descriptionShow less
CLINIC-CURE, a Pilot Exploratory Clinical Trial of Analytical Treatment Interruption in People With HIV With a Highly Favourable Profile
A pilot single exploratory clinical trial of ATI in a selected sample of PWH sharing specific genetic, phenotypic and clinical characteristics.
Inclusion: Men or women aged 18 and ≤65 years old who were screened and pre-selected in the exploratory study HCB/2023/0510 and who provide written informed consent to participate; Having a favourable genotype AND a favourable NK phenotype defined by; the presence of HLAB35 +, Bw4 > 1 + 2 threonine or HLA Bw4 > 2 + 2 threonine AND; the presence of a percentage > 16% in NK memory-like cells displaying CD57+, NKG2C, KIR3DL1 and KIR2DL3 markers; On active ART for a minimum of 2 years; Undetectable VL at the moment of inclusion and ATI; CD4 counts ≥500 at the moment of ATI; CD4 T cell count nadir ≥ 200 (for people who was diagnosed in primary infection) and ≥ 350 (for chronic infections); Participant agrees to follow HIV preventive practices; Women of child-bearing potential* must have a negative pregnancy test in serum or urine before the inclusion in the study.
Exclusion: Current or previous use of Long-acting injectable ART; Receipt of broadly neutralising antibodies within the past 2 years; 2 or more VL determinations > 50 copies/ml in the 2 years previous to ATI; Any concomitant immunosuppressive medication; Active HBV or HCV co-infection (defined by positive HBs Antigen and positive HCV-RNA); Past or current evidence of severe opportunistic infection such as CMV retinitis or cryptococcalmeningitis; Active or substantial cardiovascular, kidney or liver disease; Current cancer of any type or any history of HIV-related cancer; Active or latent tuberculosis infection; Any significant co-morbidity at discretion of the investigator that may be jeopardized in case of incomplete HIV viral suppression; History of antiretroviral drug resistance and no other options beyond their current regimen; Pregnant or breastfeeding; Men or women of childbearing potential unable or unwilling to use highly efficient contraceptive measures** from the beginning until the end of the study.